未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 COMPARED TO D2C7-IT CED MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM) 探究通过促进增强递送（CED）途径瘤内给药D2C7-IT与FC工程化抗人CD40单克隆抗体（2141-V11）联合应用，并随后进行2141-V11颈部淋巴周围注射（CPLIS）与D2C7-IT CED单药治疗相比，在复发性胶质母细胞瘤（RGBM）患者中的效果。 Desjardins, Annick; Chandramohan, Vidya; Herndon II, James E.; Bradbury, Claire; Shoaf, Madison; Peters, Katherine B.; Johnson, Margaret O.; Batich, Kristen; Low, Justin; Khasraw, Mustafa; Friedman, Allan H.; Friedman, Henry S.; Ashley, David M.; Grant, Gerald; Osorio, Juan; Ravetch, Jeffrey; Bigner, Darell D. 分享 收藏
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial 与接受vorasidenib或安慰剂治疗的Grade 2，异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者中，体素（3D）评估相较于传统双向（2D）评估在INDIGO III期试验中的比较 Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F. 分享 收藏
Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment 水通道蛋白-4在星形胶质细胞中的丢失驱动胶质母细胞瘤相关的脑水肿并改变肿瘤免疫微环境 Joshi, Tanvi; Flick, Matthew J.; Garvin, Kaisha; Vallcorba, Montserrat Puigdelloses; Dedhia, Mehek; Chen, Zhihong; Peters, Katherine B.; Ramos, Susana Isabel; Tsankova, Nadejda; Tran, Nhan L.; Hu, Leland S.; Smith, Alex J.; Heiland, Dieter Henrik; Hambardzumyan, Dolores 分享 收藏
分享 收藏
A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO2TM combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE 一项关于NanO2TM联合放射治疗和替莫唑胺治疗新诊断胶质母细胞瘤的II期双盲、随机、前瞻性、安慰剂对照研究：RESTORE Badruddoja, Michael; Placencia, Crystal; Goldlust, Samuel; Peters, Katherine; Stea, Baldassarre; Newton, Herbert; Cohen, Adam; Blondin, Nicholas; Aiken, Robert; Goldin, Caroline; Kong, Xiao-Tang; Tsung, Andrew; Wagle, Naveed; Mahadevan, Daruka; Huang, Claire; Johnson, Jeremy; Unger, Evan 分享 收藏
分享 收藏
分享 收藏
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial 体积肿瘤生长率（TGR）建模预测了在INDIGO三期试验中，接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者的临床结局。 Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F. 分享 收藏
PHASE 2, MULTICENTER, RANDOMIZED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB IN PATIENTS WITH HIGH-GRADE ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA II期，多中心，随机临床试验，旨在评估Safusidenib在IDH1（异柠檬酸脱氢酶1）突变的高级别胶质瘤患者中的有效性和安全性。 Reardon, David; Umemura, Yoshie; Peters, Katherine; Mao, Ying; Cen, Yuling; Wei, Jianxin; Thomas, Piia; Iwamoto, Fabio 分享 收藏
TARGETING FGFR ALTERATIONS IN GLIOMAS: A SINGLE-INSTITUTION CASE SERIES 靶向FGFR改变在胶质瘤中的应用：一项单机构病例系列研究 Shoaf, Madison L.; Patel, Mallika P.; Ashley, David M.; Batich, Kristen; Friedman, Henry S.; Johnson, Margaret O.; Khasraw, Mustafa; Low, Justin T.; Peters, Katherine B.; Desjardins, Annick 分享 收藏
An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients 对Tumor Monorail Device (TMD)进行重复采样的评估，作为一项评估通过对流增强递送（CED）和颈周淋巴间隙注射（CPLIs）分别经瘤内给予D2C7-IT以及Fc工程化抗CD40单克隆抗体（2141-V11）的联合方案在复发性胶质母细胞瘤（rGBM）患者中疗效试验的一部分。 Desjardins, Annick; Chandramohan, Vidya; Mokarram, Nassir; Meehan, Sean; Sharma, Shaili; Herndon Ii, James E.; Shoaf, Madison; Peters, Katherine B.; Johnson, Margaret O.; Batich, Kristen; Low, Justin; Khasraw, Mustafa; Friedman, Allan H.; Friedman, Henry S.; Ashley, David M.; Grant, Gerald; Osorio, Juan; Ravetch, Jeffrey; Bellamkonda, Ravi; Bigner, Darell D. 分享 收藏
Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results lerapolturev与洛莫司汀在复发性胶质母细胞瘤(rGBM)中的随机化Ⅱ期临床试验：重复肿瘤内和颈部淋巴周围注射(CPLIs)的安全导引入组结果 Shoaf, Madison L.; Gromeier, Matthias; Brown, Michael C.; Buckley, Evan D.; Herndon II, James E.; Batich, Kristen; Johnson, Margaret O.; Khasraw, Mustafa; Low, Justin T.; Peters, Katherine B.; Friedman, Allan H.; Friedman, Henry S.; Ashley, David M.; Bigner, Darell D.; Desjardins, Annick 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
NEURO-ONCOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏